肝细胞癌患者来伐替尼诱发掌跖红肌麻痹综合征的风险因素：一项回顾性研究

IF 2.9 2区医学 Q2 ONCOLOGY Cancer Medicine Pub Date : 2024-08-27 DOI:10.1002/cam4.70065

Shusuke Uekusa, Maho Nemoto, Yuki Hanai, Misaki Nakashin, Sachiko Yanagino, Yoshiki Arita, Takahiro Matsumoto, Noritaka Wakui, Hidenari Nagai, Koji Higai, Kazuhiro Matsuo

{"title":"肝细胞癌患者来伐替尼诱发掌跖红肌麻痹综合征的风险因素：一项回顾性研究","authors":"Shusuke Uekusa, Maho Nemoto, Yuki Hanai, Misaki Nakashin, Sachiko Yanagino, Yoshiki Arita, Takahiro Matsumoto, Noritaka Wakui, Hidenari Nagai, Koji Higai, Kazuhiro Matsuo","doi":"10.1002/cam4.70065","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aim</h3>\n \n <p>Lenvatinib mesylate (LEN) is an oral tyrosine kinase inhibitor used to treat various cancers, including hepatocellular carcinoma (HCC). HCC treatment with LEN is associated with a very high incidence of adverse events. This study was aimed at investigating the incidence of LEN-induced palmar-planter erythrodysesthesia syndrome (PPES) and its relationship with patient demographics by analyzing clinical laboratory data of LEN-treated patients with HCC.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This was a single-centre, retrospective study of patients with HCC who received LEN between April 19, 2018, and September 30, 2020. The observation period was from 1 week before the start of LEN administration to 1 month after the end of administration.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Overall, 75 patients with HCC were enrolled. LEN-induced PPES was found in 48.0% (36/75 patients). In these patients, alkaline phosphatase (ALP), γ-Glutamyl transpeptidase (γ-GTP) and monocytes (MONO) were significantly high (ALP: <i>p</i> = 1.32 × 10<sup>−3</sup>, γ-GTP: <i>p</i> = 4.25 × 10<sup>−3</sup> and MONO: <i>p</i> = 0.013). The cut off values of ALP, γ-GTP and MONO for LEN-induced PPES were estimated at 573 U/L, 89 U/L, and 310 counts/μL, respectively. In the multivariate analysis, γ-GTP and MONO were independent risk factors for LEN-induced PPES.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>High γ-GTP and high MONO were risk factors for LEN-induced PPES.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70065","citationCount":"0","resultStr":"{\"title\":\"Risk factors for lenvatinib-induced palmar-plantar erythrodysesthesia syndrome in patients with hepatocellular carcinoma: A retrospective study\",\"authors\":\"Shusuke Uekusa, Maho Nemoto, Yuki Hanai, Misaki Nakashin, Sachiko Yanagino, Yoshiki Arita, Takahiro Matsumoto, Noritaka Wakui, Hidenari Nagai, Koji Higai, Kazuhiro Matsuo\",\"doi\":\"10.1002/cam4.70065\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Aim</h3>\\n \\n <p>Lenvatinib mesylate (LEN) is an oral tyrosine kinase inhibitor used to treat various cancers, including hepatocellular carcinoma (HCC). HCC treatment with LEN is associated with a very high incidence of adverse events. This study was aimed at investigating the incidence of LEN-induced palmar-planter erythrodysesthesia syndrome (PPES) and its relationship with patient demographics by analyzing clinical laboratory data of LEN-treated patients with HCC.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>This was a single-centre, retrospective study of patients with HCC who received LEN between April 19, 2018, and September 30, 2020. The observation period was from 1 week before the start of LEN administration to 1 month after the end of administration.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Overall, 75 patients with HCC were enrolled. LEN-induced PPES was found in 48.0% (36/75 patients). In these patients, alkaline phosphatase (ALP), γ-Glutamyl transpeptidase (γ-GTP) and monocytes (MONO) were significantly high (ALP: <i>p</i> = 1.32 × 10<sup>−3</sup>, γ-GTP: <i>p</i> = 4.25 × 10<sup>−3</sup> and MONO: <i>p</i> = 0.013). The cut off values of ALP, γ-GTP and MONO for LEN-induced PPES were estimated at 573 U/L, 89 U/L, and 310 counts/μL, respectively. In the multivariate analysis, γ-GTP and MONO were independent risk factors for LEN-induced PPES.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>High γ-GTP and high MONO were risk factors for LEN-induced PPES.</p>\\n </section>\\n </div>\",\"PeriodicalId\":139,\"journal\":{\"name\":\"Cancer Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-08-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70065\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70065\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70065","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

甲磺酸伦伐替尼（LEN）是一种口服酪氨酸激酶抑制剂，用于治疗多种癌症，包括肝细胞癌（HCC）。使用LEN治疗肝细胞癌的不良反应发生率非常高。本研究旨在通过分析接受 LEN 治疗的 HCC 患者的临床实验室数据，调查 LEN 引起的掌跖红肌麻痹综合征（PPES）的发生率及其与患者人口统计学的关系。方法这是一项单中心回顾性研究，研究对象为2018年4月19日至2020年9月30日期间接受LEN治疗的HCC患者。观察期为开始服用 LEN 前 1 周至用药结束后 1 个月。结果共纳入 75 例 HCC 患者。48.0%的患者（36/75 例）发现了 LEN 诱导的 PPES。在这些患者中，碱性磷酸酶（ALP）、γ-谷氨酰转肽酶（γ-GTP）和单核细胞（MONO）显著偏高（ALP：p = 1.32 × 10-3；γ-GTP：p = 4.25 × 10-3；MONO：p = 0.013）。估计 LEN 诱导 PPES 的 ALP、γ-GTP 和 MONO 临界值分别为 573 U/L、89 U/L、310 计数/μL。在多变量分析中，γ-GTP 和 MONO 是 LEN 诱导 PPES 的独立风险因素。结论高γ-GTP和高MONO是LEN诱发PPES的风险因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

摘要图片

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Risk factors for lenvatinib-induced palmar-plantar erythrodysesthesia syndrome in patients with hepatocellular carcinoma: A retrospective study

Aim

Lenvatinib mesylate (LEN) is an oral tyrosine kinase inhibitor used to treat various cancers, including hepatocellular carcinoma (HCC). HCC treatment with LEN is associated with a very high incidence of adverse events. This study was aimed at investigating the incidence of LEN-induced palmar-planter erythrodysesthesia syndrome (PPES) and its relationship with patient demographics by analyzing clinical laboratory data of LEN-treated patients with HCC.

Methods

This was a single-centre, retrospective study of patients with HCC who received LEN between April 19, 2018, and September 30, 2020. The observation period was from 1 week before the start of LEN administration to 1 month after the end of administration.

Results

Overall, 75 patients with HCC were enrolled. LEN-induced PPES was found in 48.0% (36/75 patients). In these patients, alkaline phosphatase (ALP), γ-Glutamyl transpeptidase (γ-GTP) and monocytes (MONO) were significantly high (ALP: p = 1.32 × 10⁻³, γ-GTP: p = 4.25 × 10⁻³ and MONO: p = 0.013). The cut off values of ALP, γ-GTP and MONO for LEN-induced PPES were estimated at 573 U/L, 89 U/L, and 310 counts/μL, respectively. In the multivariate analysis, γ-GTP and MONO were independent risk factors for LEN-induced PPES.

Conclusions

High γ-GTP and high MONO were risk factors for LEN-induced PPES.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.